[1]彭琼琳,黄 敏.高强度聚焦超声消融联合当归芍药散治疗子宫腺肌病的疗效分析[J].医学信息,2022,35(01):133-136.[doi:10.3969/j.issn.1006-1959.2022.01.032]
　PENG Qiong-lin,HUANG Min.Efficacy of High-intensity Focused Ultrasound Ablation Combined with Danggui Shaoyao Powder in the Treatment of Adenomyosis[J].Medical Information,2022,35(01):133-136.[doi:10.3969/j.issn.1006-1959.2022.01.032]
点击复制

高强度聚焦超声消融联合当归芍药散治疗子宫腺肌病的疗效分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年01期
页码:
133-136
栏目:
论著
出版日期:
2022-01-01

文章信息/Info

Title:
Efficacy of High-intensity Focused Ultrasound Ablation Combined with Danggui Shaoyao Powder in the Treatment of Adenomyosis
文章编号:
1006-1959（2022）01-0133-04
作者:
彭琼琳; 黄 敏
（鄂钢医院妇产科，湖北 鄂州 436000）
Author(s):
PENG Qiong-lin; HUANG Min
(Department of Obstetrics and Gynecology,Egang Hospital,Ezhou 436000,Hubei,China)
关键词:
当归芍药散; 子宫腺肌病; 高强度聚焦超声消融
Keywords:
Danggui Shaoyao powder; Adenomyosis; High-intensity focused ultrasound ablation
分类号:
R711.74
DOI:
10.3969/j.issn.1006-1959.2022.01.032
文献标志码:
A
摘要:
目的 分析高强度聚焦超声消融（HIFU）联合当归芍药散治疗子宫腺肌病（AM）的临床疗效。方法 选取2017年4月-2018年7月鄂钢医院妇产科收治的73例AM患者为对照组，另选取2018年8月-2020年1月的74例AM患者为观察组。对照组采用HIFU+宫内放置左炔诺孕酮宫内缓释环（LNGI-US）治疗，观察组在对照组基础上加用当归芍药散治疗。比较两组血清炎症因子白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）和超敏C反应蛋白（hs-CRP）水平及性激素前列腺素F2α（PGF2α）、糖类抗原125（CA125）、卵泡刺激素（FSH）、雌二醇（E2）和黄体生成素（LH）水平、子宫内膜厚度、病灶体积、子宫体积、痛经评分（VAS）、月经量评分（PBAC）、有效率、不良反应发生率、继发性痛经复发率。结果 治疗6个月、1年，观察组PGF2α、CA125、FSH、E2、LH水平均低于对照组（P＜0.05）；治疗6个月、1年，观察组IL-6、TNF-α和hs-CRP水平均低于对照组（P＜0.05）；治疗6个月、1年，观察组VAS和PBAC评分及子宫内膜厚度、病灶体积、子宫体积均低于对照组（P＜0.05）；观察组更年期症状、疲劳乏力、胃肠道反应、阴道分泌物增多、绝经发生率均低于对照组（P＜0.05）；观察组继发性痛经复发率低于对照组，治疗总有效率高于对照组（P＜0.05）。结论 当归芍药散可能通过抑制炎症反应并调节性激素水平而影响子宫内膜生理功能，可提高HIFU治疗AM的临床疗效，降低继发性痛经复发率，且不良反应发生率低，安全性高。
Abstract:
Objective To analyze the clinical efficacy of high intensity focused ultrasound ablation (HIFU) combined with Danggui Shaoyao powder in the treatment of adenomyosis (AM).Methods A total of 73 patients with AM admitted to the Obstetrics and Gynecology Department of Egang Hospital from April 2017 to July 2018 were selected as the control group, and 74 patients with AM from August 2018 to January 2020 were selected as the observation group. The control group was treated with HIFU and levonorgestrel intrauterine slow-release ring (LNGI-US), and the observation group was treated with Danggui Shaoyao powder on the basis of the control group. The levels of serum inflammatory cytokines interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and high-sensitivity C-reactive protein (hs-CRP), sex hormone prostaglandin F2α (PGF2α), carbohydrate antigen 125 (CA125), follicle stimulating hormone (FSH), estradiol (E2) and luteinizing hormone (LH), endometrial thickness, lesion volume, uterine volume, dysmenorrhea score (VAS), menstrual volume score (PBAC), effective rate, incidence of adverse reactions, and recurrence rate of secondary dysmenorrhea were compared between the two groups.Results After 6 months and 1 year of treatment, the levels of PGF2α, CA125, FSH, E2 and LH in the observation group were lower than those in the control group (P<0.05). After 6 months and 1 year of treatment, the levels of IL-6, TNF-α and hs-CRP in the observation group were lower than those in the control group (P<0.05). After 6 months and 1 year of treatment, the VAS and PBAC scores, endometrial thickness, lesion volume and uterine volume in the observation group were lower than those in the control group (P<0.05). The incidence of menopausal symptoms, fatigue, gastrointestinal reactions, increased vaginal secretions and menopause in the observation group were lower than those in the control group (P<0.05). The recurrence rate of secondary dysmenorrhea in the observation group was lower than that in the control group, and the total effective rate in the treatment group was higher than that in the control group(P<0.05).Conclusion Danggui Shaoyao powder may affect the physiological functions of the endometrium by inhibiting inflammation and regulating the level of sex hormones. It can improve the clinical efficacy of HIFU in the treatment of AM, reduce the recurrence rate of secondary dysmenorrhea, and have low incidence of adverse reactions and high safety.

参考文献/References:

[1]张晓丽,李晶晶,谭广萍,等.腹腔镜病灶切除术后联合药物序贯治疗子宫腺肌病的效果[J].医学信息,2020,33(3):102-104.[2]Xia W,Zhang D,Ouyang J,et al.Effects of pelvic endometriosis and adenomyosis on ciliary beat frequency and muscular contractions in the human fallopian tube[J].Reprod Biol Endocrinol,2018,16(1):48-51.[3]马荣丽,关铮,刘爱军,等.前列腺素F(2α)受体与子宫腺肌病痛经的相关性研究[J].解放军医学院学报,2015,15(4):355-358.[4]张雪春,胡晓东.子宫腺肌症患者经左炔诺孕酮宫内缓释系统联合戈舍瑞林治疗的随访研究[J].哈尔滨医药,2021,41(1):86-87.[5]邵永红,王芸.散结镇痛胶囊联合曼月乐治疗子宫腺肌病临床效果及安全性评价[J].实用药物与临床,2013,16(11):1038-1041.[6]冯欣,窦曦,沈庆波,等.高强度聚焦超声治疗子宫腺肌瘤消融率的影响因素分析[J].医学信息,2020,33(20):91-93.[7]罗爽,王艳,何佳,等.高强度聚焦超声消融联合孕三烯酮治疗子宫腺肌病的疗效评价[J].重庆医学,2018,47(2):170-172.[8]保艳.当归芍药散在妇科疾病中的应用[J].光明中医,2020,35(6):910-912.[9]韦秀玉,来玉芹.当归芍药散加减治疗胚胎移植术后子宫痉挛性疼痛疗效观察[J].实用中医药杂志,2019,35(2):49-50.[10]张建英,楚更五,刘秀萍,等.当归散对正常和缩宫素处理大鼠离体子宫活动力的影响[J].中国实验方剂学杂志,2011,17(7):201-203.[11]华永庆,洪敏,李璇,等.当归、芍药、香附及其配伍对离体小鼠子宫痛经模型的影响[J].浙江中医杂志,2003,38(1):26-27.[12]丁岩华,永庆,林紫微,等.当归芍药散对围绝经期模型大鼠子宫结构及雌激素受体表达的影响[J].中国药房,2017,28(34):4788-4792.[13]闫亚楠,刘敏,高升,等.采用正交设计析因分析法对当归芍药散治疗慢性盆腔炎模型大鼠的组方优化研究[J].中药药理与临床,2018,34(5):13-17.[14]夏宛廷,梁潇元,耿静然,等.《金匮要略》当归芍药散治疗痛经之浅析[J].中国中医急症,2017,26(3):451-453.[15]罗茜,兰培敏,彭旭,等.当归芍药散治疗女性黄褐斑疗效及对性激素水平的影响[J].现代中西医结合杂志,2019,28(11):1188-1191.[16]刘明敏,李伟莉.徐氏妇科应用当归芍药散治疗妇科疾病经验[J].现代中医药,2019,39(3):6-9.[17]Brenner RM,Nayak NR,Slayden OD,et al.Premenstrual and menstrual changes in the macaque and human endometrium:relevance to endometriosis[J].Ann N Y Acad Sci,2002,9(55):60-74.[18]Mazur EC,Large MJ,Demayo FJ.Chapter 24 - Human Oviduct and Endometrium: Changes over the Menstrual Cycle[J].Knobil and Neill’s Physiology of Reproduction (Fourth Edition),2015:1077-1097.[19]Kitawaki J.Adenomyosis:the pathophysiology of an oestrogen-dependent disease[J].Best Pract Res Clin Obstet Gynaecol,2006,20(4):493-502.[20]Claudia T,Libera T,Silvia V,et al.Current and Future Medical Treatment of Adenomyosis[J].Journal of Endometriosis and Pelvic Pain Disorders,2018,8(4):127-135.

相似文献/References:

[1]翟 蓓,周 洋,周 薇,等.超声检查、磁共振及血清CA125测定诊断 子宫腺肌病的临床评价[J].医学信息,2018,31(11):154.[doi:10.3969/j.issn.1006-1959.2018.11.050]
　ZHAI Bei,ZHOU Yang,ZHOU Wei,et al.Clinical Evaluation of Ultrasonography,Magnetic Resonance Imaging and Serum CA125 in Diagnosis of Adenomyosis[J].Medical Information,2018,31(01):154.[doi:10.3969/j.issn.1006-1959.2018.11.050]
[2]杨 霞,陈亚兰.左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床观察[J].医学信息,2019,32(14):117.[doi:10.3969/j.issn.1006-1959.2019.14.037]
　YANG Xia,CHEN Ya-lan.Clinical Observation of Levonorgestrel Intrauterine Sustained Release System in the Treatment of Adenomyosis[J].Medical Information,2019,32(01):117.[doi:10.3969/j.issn.1006-1959.2019.14.037]
[3]张晓丽,李晶晶,谭广萍,等.腹腔镜病灶切除联合序贯使用亮丙瑞林及优思明在子宫腺肌病中的应用[J].医学信息,2020,33(03):102.[doi:10.3969/j.issn.1006-1959.2020.03.029]
　ZHANG Xiao-li,LI Jing-jing,TAN Guang-ping,et al.The Effect of Sequential Drug Treatment on Adenomyosis After Laparoscopic Focal Resection[J].Medical Information,2020,33(01):102.[doi:10.3969/j.issn.1006-1959.2020.03.029]
[4]李 娟,胡 欣,张小妹.米非司酮联合血府逐瘀汤治疗子宫腺肌病的临床观察[J].医学信息,2021,34(23):168.[doi:10.3969/j.issn.1006-1959.2021.23.051]
　LI Juan,HU Xin,ZHANG Xiao-mei.Clinical Observation of Mifepristone Combined with Xuefu Zhuyu Decoction in the Treatment of Adenomyosis[J].Medical Information,2021,34(01):168.[doi:10.3969/j.issn.1006-1959.2021.23.051]
[5]彭琼琳,黄 敏.超声消融结合中药治疗子宫腺肌病继发性痛经的效果[J].医学信息,2021,34(17):157.[doi:10.3969/j.issn.1006-1959.2021.17.042]
　PENG Qiong-lin,HUANG Min.The Effect of Ultrasonic Ablation Combined with Traditional Chinese Medicine in the Treatment of Secondary Dysmenorrhea Caused by Adenomyosis[J].Medical Information,2021,34(01):157.[doi:10.3969/j.issn.1006-1959.2021.17.042]

更新日期/Last Update: 1900-01-01